State Street’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.11B Buy
26,296,399
+304,875
+1% +$25.1M 0.07% 241
2025
Q4
$2.22B Buy
25,991,524
+371,892
+1% +$30.5M 0.07% 223
2025
Q3
$1.99B Sell
25,619,632
-14,746
-0.1% -$1.15M 0.07% 242
2025
Q2
$2B Sell
25,634,378
-149,084
-0.6% -$11.1M 0.08% 235
2025
Q1
$1.87B Sell
25,783,462
-25,160
-0.1% -$1.8M 0.08% 239
2024
Q4
$1.91B Sell
25,808,622
-457,011
-2% -$32M 0.08% 231
2024
Q3
$1.73B Buy
26,265,633
+256,538
+1% +$18.6M 0.07% 255
2024
Q2
$2.4B Sell
26,009,095
-766,690
-3% -$67.9M 0.11% 170
2024
Q1
$2.56B Sell
26,775,785
-179,865
-0.7% -$15.1M 0.11% 163
2023
Q4
$2.06B Buy
26,955,650
+507,914
+2% +$35.3M 0.1% 196
2023
Q3
$1.83B Sell
26,447,736
-605,568
-2% -$48.7M 0.1% 189
2023
Q2
$2.55B Buy
27,053,304
+108,102
+0.4% +$9.4M 0.13% 144
2023
Q1
$2.23B Sell
26,945,202
-355,964
-1% -$28M 0.13% 154
2022
Q4
$2.04B Buy
27,301,166
+493,844
+2% +$38.1M 0.12% 170
2022
Q3
$2.22B Sell
26,807,322
-90,807
-0.3% -$8.74M 0.14% 144
2022
Q2
$2.56B Sell
26,898,129
-23,657
-0.1% -$2.45M 0.15% 134
2022
Q1
$3.17B Buy
26,921,786
+1,073
+0% +$120K 0.16% 124
2021
Q4
$3.49B Buy
26,920,713
+948,638
+4% +$111M 0.17% 116
2021
Q3
$2.94B Buy
25,972,075
+252,381
+1% +$28.8M 0.16% 120
2021
Q2
$2.66B Sell
25,719,694
-7,197
-0% -$678K 0.14% 130
2021
Q1
$2.15B Sell
25,726,891
-134,815
-0.5% -$11.4M 0.12% 158
2020
Q4
$2.36B Sell
25,861,706
-893,253
-3% -$74.1M 0.14% 134
2020
Q3
$2.14B Sell
26,754,959
-493,061
-2% -$38.5M 0.15% 137
2020
Q2
$1.88B Buy
27,248,020
+251,299
+0.9% +$17.9M 0.14% 151
2020
Q1
$1.7B Buy
26,996,721
+245,928
+0.9% +$17.7M 0.15% 139
2019
Q4
$2.08B Buy
26,750,793
+363,555
+1% +$28.4M 0.14% 146
2019
Q3
$1.93B Sell
26,387,238
-134,115
-0.5% -$9.42M 0.14% 157
2019
Q2
$1.63B Sell
26,521,353
-70,788
-0.3% -$4.28M 0.12% 173
2019
Q1
$1.7B Buy
26,592,141
+1,108,641
+4% +$63.3M 0.13% 155
2018
Q4
$1.3B Sell
25,483,500
-96,522
-0.4% -$4.88M 0.12% 172
2018
Q3
$1.48B Buy
25,580,022
+860,043
+3% +$42.1M 0.11% 176
2018
Q2
$1.2B Sell
24,719,979
-411,204
-2% -$19.2M 0.1% 199
2018
Q1
$1.17B Sell
25,131,183
-1,006,992
-4% -$43.7M 0.1% 204
2017
Q4
$982M Sell
26,138,175
-392,376
-1% -$14.4M 0.08% 260
2017
Q3
$967M Sell
26,530,551
-778,593
-3% -$29.7M 0.08% 252
2017
Q2
$1.08B Sell
27,309,144
-857,838
-3% -$31.3M 0.1% 219
2017
Q1
$883M Buy
28,166,982
+473,532
+2% +$14.8M 0.08% 263
2016
Q4
$865M Buy
27,693,450
+1,229,697
+5% +$39.8M 0.08% 260
2016
Q3
$1.06B Buy
26,463,753
+579,039
+2% +$21.8M 0.11% 208
2016
Q2
$861M Sell
25,884,714
-1,304,847
-5% -$44.6M 0.09% 240
2016
Q1
$799M Sell
27,189,561
-375,441
-1% -$10.4M 0.09% 245
2015
Q4
$726M Buy
+27,565,002
New +$716M 0.08% 264
2015
Q2
Sell
-28,961,760
Closed -$688M 3731
2015
Q1
$688M Sell
28,961,760
-667,656
-2% -$15M 0.07% 291
2014
Q4
$629M Buy
29,629,416
+1,507,872
+5% +$30.3M 0.06% 313
2014
Q3
$479M Buy
28,121,544
+375,342
+1% +$5.92M 0.05% 357
2014
Q2
$397M Sell
27,746,202
-199,800
-0.7% -$2.71M 0.04% 410
2014
Q1
$345M Sell
27,946,002
-1,297,278
-4% -$15M 0.04% 429
2013
Q4
$321M Buy
29,243,280
+247,020
+0.9% +$2.78M 0.04% 446
2013
Q3
$337M Buy
28,996,260
+147,948
+0.5% +$1.73M 0.04% 418
2013
Q2
$323M Buy
+28,848,312
New +$341M 0.04% 405

Other funds holding EW

State Street's EW Position: Q1 2026 in Review

State Street increased its Edwards Lifesciences (EW) stake by 1.2% in Q1 2026, buying an estimated $25.1M and bringing the position to 26,296,399 shares worth $2.11B. The position accounts for 0.07% of the portfolio, ranked #241.

State Street first reported a position in EW in Q2 2013 and has held it in 50 quarters since. The position peaked at $3.49B in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • State Street held 26,296,399 shares of Edwards Lifesciences worth $2.11B as of Q1 2026.
  • State Street bought 304,875 Edwards Lifesciences shares in Q1 2026, an estimated $25.1M.
  • Edwards Lifesciences made up 0.07% of State Street's portfolio in Q1 2026, its #241 holding.
  • State Street first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 50 quarters since.
  • State Street's Edwards Lifesciences position peaked at $3.49B in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.